Korean J Anesthesiol.  1983 Jun;16(2):145-151.

Midazolam Malate as an Intravenous Induction Agent for Open Heart Surgery

Affiliations
  • 1Department of Anesthesiology,Yonsei University College of Medicine, Seoul, Korea.

Abstract

Midazolam, a water-soluble benzodiazepine that is shorter-acting, more potent, and less irritating to veins than diazepam, has been suggested for use for induction of anesthesia. The cardiovascular effects of an induction dose(0.2~0.3mg/kg) of midazolam in ASA class lll cardiac surgical patients (N=15) were compared in a couble-blind fashion with a similar group of patients (N=15) receiving thiopental (5.0mg/kg). The patients were premedicated by triflupromasine, pethidine, hydroxyzine, atropine and diazepam. The results were summarized as follows. 1) The thiopental group were more decreased in blood pressure and increase in heart rates than midazolam group. 2) Spontaneous eye closing time and loss of eyelash reflexes were observed. But those were a poor sign of adequate induction became of heavy preanesthetic sedation. 3) The changes of blood pressure and pulse rate after induction and intubation were almost similar in the two groups, but greater individual variation was seen in midazolam groups, depends on preload state before induction. From the above results, midazolam was sufficient as an induction agent for open heart cases. But a hypovolemic patients and completely beta blocked patients should be used cautiously because they may be developed severe hypotension and tachycardia.


MeSH Terms

Anesthesia
Atropine
Benzodiazepines
Blood Pressure
Diazepam
Heart Rate
Heart*
Humans
Hydroxyzine
Hypotension
Hypovolemia
Intubation
Meperidine
Midazolam*
Reflex
Tachycardia
Thiopental
Thoracic Surgery*
Veins
Atropine
Benzodiazepines
Diazepam
Hydroxyzine
Meperidine
Midazolam
Thiopental
Full Text Links
  • KJAE
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr